You are here

PHYSIOLOGICAL CONTROLLER FOR ROTARY BLOOD PUMPS

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: N/A
Agency Tracking Number: 1R43HL066656-01
Amount: $98,465.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2001
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
3500 5TH AVE, STE 203
PITTSBURGH, PA 15213
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 DANIEL ONEIL
 () -
Business Contact
Phone: (412) 802-6431
Email: ANTAKAMATICS@YAHOO.COM
Research Institution
N/A
Abstract

DESCRIPTION (Verbatim From Applicant's Abstract): As the prospects of a
mechanical replacement for a failing human heart are fast becoming a reality,
and patients are indeed returning home to regain a "normal" lifestyle, the
limitations of this technology upon quality of life are becoming more apparent.
To address many of these limitations, investigators are developing
next-generation ventricular assist devices. Based on turbopump technology,
these new devices offer smaller size, greater efficiency (hence smaller
batteries), high reliability, and are more cost effective as compared to their
pulsatile predecessessors. For all the virtues of these new turbopumps, they
bring with additional challenges. Arguably the most urgent is the need for
added intelligence." These, relatively stupid, devices are highly dependent on
feedback-control to provide physiological response. Unfortunately, developers
have yet to wage a systematic assault on this problem. Preoccupied with
apparently more urgent issues, such as biocompatibility etc., there has been
relatively little attention or resources directed at developing a physiological
controller.

For the past eight years, the P.I. has had an interest in this problem, and has
conducted basic and applied research towards developing control algorithms. He
now proposes to devise a general-purpose controller product, which can be
incorporated into a variety of rotary pump systems for clinical use.

The goal of the Phase-I effort proposed herein are to design a robust control
algorithm which may then be implemented, in Phase-Il, into an applications
specific integrated circuit. The P.I. envisions that this chip would be
made available to device developers much like control circuits produced by
Intel, Motorola, Texas Instruments, etc., are adopted by a wide variety of
users for their specific products.
PROPOSED COMMERCIAL APPLICATION:
Direct application to virtually all rotary-type blood pumps for critical care and chronic use.
The P.I. envisions that the Antakamatics control chip would be made available to device
developers much like integrated circuits producted by Intel, Motorola, Texas Instruments,
etc. are adopted by a wide variety of users for their specific products. The market for
this product is estimated to exceed 200,000 units per annum, and there currently exists
no competing product.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government